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Safety and efficacy of xenon in routine use as an
inhalational anaesthetic
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40 patients (24 male, 16 female, aged 21-59 years)
of American Society of Anesthesiologists class I or
II who were undergoing routine surgery took part
in a randomised, double-blind comparison of the
anaesthetic efficacy and potency of xenon and
nitrous oxide and their effects on the circulatory
and respiratory systems. During anaesthesia, for
each rise in blood pressure of more than 20% of the
preanaesthetic (baseline) value, the patient
received 0&middot;1 mg fentanyl. The total amount of
fentanyl required per patient was used as an index
of the anaesthetic potency of the study gases.
Patients in the xenon group required on average
only 0&middot;05 mg fentanyl, whereas those in the nitrous
oxide group required 0&middot;24 mg fentanyl; the
duration of anaesthesia was similar in the two
groups. Changes in blood pressure were
significantly greater throughout the study in the
nitrous oxide than in the xenon group. Thorax-lung
compliance fell during the study period in the
nitrous oxide group but not in the xenon group.
Thus, xenon is a potent and effective anaesthetic
which can be safely used under routine conditions.
Introduction
The anaesthetic gases and vapours in routine use have
undesirable side-effects on both patients and medical and
nursing staff and are a source of pollution of the
environment.1-6 The search continues, therefore, for a gas
that meets all the requirements for an anaesthetic agent but
has none of these disadvantages. Xenon offers many
advantages over routinely used gases.7 It is non-explosive;
probably does not undergo biotransformation; is non-toxic;
and offers rapid induction of and recovery from
anaesthesia.8-11 In experimental studies we have measured
tooth-pulp evoked potentials to evaluate pain12,13 and
confirmed that the analgesic efficacy of xenon is superior to
that of nitrous oxide at the same concentration (70%);14
xenon had no effect on systemic haemodynamics or local
organ perfusion15 as measured by means of radionuclide-
labelled microspheres.16,17
The main reason why xenon is not routinely used is that
there have been no commercially available anaesthesia
machines in which to use the gas, which is more expensive
than nitrous oxide and the volatile anaesthetics. There has
been very limited clinical experience with xenon,8-11 and no
studies have compared its anaesthetic efficacy and effects on
haemodynamics and lung mechanics with those of the "gold
standard", nitrous oxide. We have investigated the
anaesthetic efficacy of a mixture of 70% xenon/30% oxygen
and 70% nitrous oxide/30% oxygen, incorporated in a
balanced anaesthetic method, in a randomised double-blind
study during routine surgery.
Before induction of anaesthesia, baseline blood pressure
levels were established for each patient. In accordance with
the balanced anaesthesia method, rises in blood pressure of
more than 20% of the baseline value were treated with 0-1
mg fentanyl intravenously. The total amount of fentanyl
required for each patient was taken as an objective index of
the potency and overall efficacy of the two gases.
Patients and methods
40 patients (24 men, 16 women; aged 21-59 years, American
Society of Anesthesiologists [ASA] class I or II) undergoing routine
operations of similar durations gave written informed consent to
take part in the study. The study protocol was approved by the
hospital medical ethics review committee. The patients were
randomised as follows: plastic surgery to face, breast, or genitals 2 to
xenon, 4 to nitrous oxide; intraperitoneal procedures 3 to xenon, 2 to
nitrous oxide; bloodless surgery of limbs 8 to xenon, 7 to nitrous
oxide; other orthopaedic procedures 7 to each group.
All patients received methylatropine bromide (0-002 mg/kg
intravenously) as premedication. After preoxygenation (with pure
oxygen) for about 5 min (partial denitrogenation by way of a face
mask), anaesthesia was induced with intravenous thiopentone (5-7
mg/kg) and pancuronium bromide (0’1 mg/kg), then endotracheal
intubation was carried out. Further denitrogenation was brought
about by ventilation with pure oxygen for about 6-8 min. The
anaesthetic gas mixture, either xenon/oxygen (70/30) or nitrous
oxide/oxygen (70/30), was administered by means of a closed-
circuit anaesthesia machine (a combination of a ’Servoventilator
900c’ with a modified ’985 Anesthesia Circle’, Siemens Elema,
Solna, Sweden). To ensure double-blinding, the anaesthetic gases
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TABLE I-CLINICAL DATA FOR STUDY GROUPS
were administered by anaesthetists other than those responsible for
patient treatment and data collection. Minute ventilation was set to
maintain end-tidal carbon dioxide at 4-0-4-5 vol%. After wash-in of
the study gas to about 70%, the fresh gas flow was adjusted to
maintain an inspired oxygen concentration of about 30%; the
surgical procedure was then started. For each patient, if the blood
pressure rose by more than 20% of the baseline value, intravenous
fentanyl (01 mg) was given. Muscle relaxation was monitored by
means of a ’Relaxograph’ (Datex Medical, Finland) and additional
doses of pancuronium bromide were given as required. At the end
of the surgical procedure residual muscle relaxation was
antagonised by methylatropine bromide (0-035 mg/kg) and
neostigmine (0-04 mg/kg) and the study gas was washed out
by ventilation with pure oxygen. The time from withdrawal of
the study gas to return of consciousness was recorded and all
patients were interviewed after 30 min and after 24 h to evaluate
peroperative awareness and general patient acceptability
postoperatively.
At baseline (after wash-in of the study gas to 70%) and
continuously throughout the operation we monitored vital
measurements including heart rate, non-invasive systolic/diastolic
blood pressure (measured every 3 min) (Marquette monitor series
7000), arterial saturation (N-100 ’Pulsoximeter’, Nellcor, USA),
end-tidal carbon dioxide (analyser 930, Siemens Elema); and lung
mechanical measurements including thorax-lung compliance
(calculated from the ratio of tidal volume and the corresponding
change in elastic static pressure) and expiratory airway resistance
(the ratio of driving pressure [end-inspiratory pause pressure minus
expiratory airway pressure] and initial expiratory flow; Lung
Mechanics Calculator 940, Siemens Elema, Sweden). The lung
mechanics calculator is a reliable and accurate measure of lung
mechanics.18 All these measurements were automatically stored
once a minute (as available) on-line by means of an IBM-compatible
personal computer.
During anaesthesia the closed-circuit system was flushed with
fresh gas every 20 min to avoid accumulation of nitrogen.
Ventilation with one or two sighs was applied if oxygen saturation
fell below 95% at an inspired oxygen concentration of 30%.
To avoid excessive influence by individual variability, baseline
values of physiological measurements were set at 100%; further
analysis was made on the percentage values at the specified times.
Group differences in gender and ASA classification were analysed
by the Kruskal-Wallis test and those in age, weight, and height by
the chi-square test. All other variables were analysed by the
Mann-Whitney-Wilcoxon test for between-group comparison or
the sign test for paired samples for within-group comparison. All
tests of statistical significance were two-tailed and data were tested
at the 0-05 significance level. All values are presented as mean and
standard deviation.
Results
The two study groups were comparable in age, weight,
height, sex, ASA classification, duration of closed-circuit
anaesthesia, and duration of surgery (table r). However, the
average amount of fentanyl required was about five times
greater (p < 0-001) in the nitrous oxide group than in the
xenon group (table n). 13 of the 20 (65%) xenon-treated
patients required no fentanyl compared with only 1 patient
(5%) in the nitrous oxide group (table III). Changes in
systolic blood pressure throughout the operations were
significantly smaller (p <0’01) in the xenon group than in
the nitrous oxide group (see accompanying figure). Diastolic
blood pressure and pulse measurements are shown in
table II.
Peripheral arterial oxygenation was sufficient in both
groups with an inspired oxygen concentration of about
30%, and there was no difference in oxygen saturation
between the groups at the end of the operation. However, in
8 nitrous-oxide-treated patients oxygen saturation fell below
92 % during the first 20 min after induction; at the same time
there was also a fall in thorax-lung compliance of more than
20%. After treatment with one or two sighs with a double
tidal volume, thorax-lung compliance was partly restored
and oxygen saturation rose to about 96 %. The total number
of sighs was significantly higher in the nitrous oxide (n = 43)
than in the xenon group (n = 6), but thorax-lung compliance
was significantly lower in the nitrous oxide group at the end
of anaesthesia than at baseline (84 [10-5]%) and than in the
xenon group at the end of anaesthesia (97-5 [7’6]%).
Expiratory lung resistance was significantly higher in both
groups at the end of anaesthesia (xenon 116 [19] %; nitrous
oxide 129 [48] % ) than at baseline but the difference
between the groups was not significant.
Recovery time from anaesthesia was similar in both
groups (xenon 4 [3] min, nitrous oxide 7 [4] min). Only the 5
patients in the nitrous oxide group who received more than
0-4 mg fentanyl had long recovery times and took longer to
orientate themselves clearly. No patient complained of
TABLE N&mdash;MEAN (SD) PERCENTAGE CHANGES FROM BASELINE VALUES IN CIRCULATORY MEASUREMENTS
RELATED TO FENTANYL DOSE
. 
= significant difference from baseline, t = significant difference between treatment groups, p < 0 05
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TABLE III-AMOUNT OF FENTANYL REQUIRED PER PATIENT
Distribution of all measured systolic blood-pressure changes
from baseline values during anaesthesia.
peroperative awareness. Patients treated with xenon,
however, reported "nice feelings and pleasant dreams",
without being able to remember any details. The anaesthetic
course of all forty procedures was uneventful, as was the
postoperative period.
Discussion
This study shows that a concentration of 70% xenon results
in satisfactory anaesthesia for surgical procedures. The
requirement for fentanyl in the xenon group was only a fifth
of that in the nitrous oxide group and 95 % of the patients
treated with nitrous oxide required fentanyl compared with
only 35% in the xenon-treated group. The lower opioid
consumption during xenon anaesthesia, combined with the
very fast elimination of xenon, may explain the faster
recovery after xenon than after nitrous oxide.
With both anaesthetic regimens blood pressure and heart
rate were adequately controlled. The overall smaller rise in
blood pressure in the xenon group than in the nitrous oxide
group indicates more stable cardiocirculatory conditions as a
result of less stress-induced sympathetic stimulation; this
was confirmed by the fmding that adrenaline levels did not
change during the operation in the xenon group only.19 The
difference may be due to the more potent analgesic effect
(peripherally and/or centrally) of xenon.
Oxygen saturation fell below 92% in 8 patients in the
nitrous oxide group but in no patient in the xenon group.
Nitrous oxide is more soluble than xenon, which could lead
to absorptive atelectasis. This explanation is supported by
the fmding that thorax-lung compliance fell at the same
time, but it remains speculative because we did not measure
functional residual capacity in these patients at the same
time. There was only slight deterioration in lung mechanics
during xenon anaesthesia, which suggests that xenon can be
used safely in older patients and those with chronic lung
diseases.
The absence of cardiovascular side-effects, the lack of
reduction in local organ perfusion (especially in heart and
brain),15 and the established potency as an inhaled
anaesthetic and analgesic14 make xenon a very promising
anaesthetic agent for routine use. Xenon does not present
the problems and hazards to patients, medical and nursing
staff, and the environment that nitrous oxide and other
volatile anaesthetics do. The average amount of xenon
required per anaesthetic procedure was 10 litres; with the
development of closed-circuit anaesthesia systems, costs of
routine xenon use can be reduced and, therefore, will not
differ substantially from those of other anaesthetic
procedures.
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